FDA “Unable” To Decide On Plan B, Seeks Comment On Dual-Status Drugs

Agency initiates advance notice of proposed rulemaking to determine whether an active drug ingredient can be marketed both Rx and OTC for the same indication.

More from Archive

More from Pink Sheet